Stockscreener 앱 받기
1.39
3.47%
-0.05
시간 외 거래:
1.40
0.01
+0.72%
In 8 Bio Inc 주식(INAB)의 최신 뉴스
D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price - Stock Titan
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
Avai Bio (AVAI) notifies SEC of late FY2026 10-K, cites financial compilation - Stock Titan
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView
Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan
[144] Nuvation Bio Inc. SEC Filing - Stock Titan
MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan
LeonaBio (NASDAQ: LONA) shareholders approve directors, EY auditor and executive pay cadence - Stock Titan
JPMorgan Cuts Upstream Bio Stock Target to Eight Dollars - sekbernews.id
Serapha Bio to take control of Boundless Bio (NASDAQ: BOLD) in cash-dividend merger - Stock Titan
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
Valion Bio (VBIO) CFO exercises 92 RSUs, holds 618 common shares after conversion - Stock Titan
Adicet Bio (ACET) investors back board nominees, pay and KPMG at 2026 meeting - Stock Titan
Valion Bio (NASDAQ: VBIO) adds $250,000 via Series B preferred share and warrant sale - Stock Titan
Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
INmune Bio (INMB) holders OK larger stock plan and evergreen share increases - Stock Titan
Boundless Bio, Inc. Files 8-K with SEC: Company Details, Stock Info, and Emerging Growth Status Revealed - Minichart
[8-K] Boundless Bio, Inc. Reports Material Event - Stock Titan
Gossamer Bio (NASDAQ: GOSS) swaps most 2027 converts into 2030 debt and equity - Stock Titan
Kyntra Bio, Inc. 8-K SEC Filing Details June 12, 2026 – Company Information, Address, and Stock Listing - Minichart
[Form 4] Boundless Bio, Inc. Insider Trading Activity - Stock Titan
Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor - Stock Titan
BioRestorative Therapies (NASDAQ: BRTX) adds $1M revolver and installs lender-backed directors - Stock Titan
Instil Bio (TIL) director Gwendolyn Binder awarded 6,500 stock options at $7.93 - Stock Titan
KALA BIO (NASDAQ: KALA) registers $350M shelf; 1-for-50 reverse split recorded - Stock Titan
[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Korro Bio (NASDAQ: KRRO) investors back directors, pay and auditor - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
TELA Bio (NASDAQ: TELA) OKs 3.5M-share incentive plan boost - Stock Titan
Climb Bio reports encouraging Phase 1b ITP data; 250 mg cohort shows durable platelet gains - TradingView
Climb Bio (CLYM) details early budoprutug Phase 1b/2a ITP results and risks - Stock Titan
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
[8-K] Bio Green Med Solution, Inc. Reports Material Event - Stock Titan
[Form 4] KYNTRA BIO, INC. Insider Trading Activity - Stock Titan
Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments - Stock Titan
Kyntra Bio receives final $4.0M holdback from AstraZeneca, completes China sale proceeds - TradingView
Climb Bio (CLYM) director receives stock options on 40,000 common shares - Stock Titan
Climb Bio (NASDAQ: CLYM) expands equity plan evergreen to cover pre-funded warrants - Stock Titan
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform - Business Wire
Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade) (NYSE:NUVB) - Seeking Alpha
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
Gossamer Bio, Inc. 8-K Filing June 2026: Annual Meeting Results and Company Information - Minichart
Climb Bio, Inc. Files Form 8-K with SEC – Corporate Information, Stock Details, and Emerging Growth Status - Minichart
Climb Bio (NASDAQ: CLYM) advances CLYM116 toward Phase 2 IgAN trial - Stock Titan
Gossamer Bio (NASDAQ: GOSS) swaps $181M converts for new debt, equity and warrants - Stock Titan
Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay - Stock Titan
Jennison Associates (NASDAQ: CABA) holds 24.27M shares, 11.4% - Stock Titan
Valion Bio (NASDAQ: VBIO) investors approve major equity plan boost and share issuances - Stock Titan
Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan
1.18%
2.48%
자본화:
|
볼륨(24시간):